Cited 4 times in
Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명수 | - |
dc.date.accessioned | 2021-09-29T02:35:23Z | - |
dc.date.available | 2021-09-29T02:35:23Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 1474-0338 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/185010 | - |
dc.description.abstract | Objectives: In TRANSFORM, de novo kidney transplant recipients received either everolimus in combination with reduced-exposure calcineurin inhibitor (EVR+rCNI) at standard EVR pre-dose concentrations of 3-8 ng/mL or mycophenolic acid plus standard-exposure CNI (MPA+sCNI). The authors analyzed the incidence of wound healing adverse events (WHAEs) over the 2-year study period 15. Methods: Patients were randomized to either EVR+rCNI or MPA+sCNI, both combined with induction therapy and steroids 19. Results: The safety population consisted of 2,026 patients (EVR+rCNI: 1,014, MPA+sCNI: 1,012). The proportion of patients with at least 1 WHAE was comparable between EVR+rCNI and MPA+sCNI treatment groups [20.6% vs. 17.3%; risk ratio (RR): 1.19; 95% confidence interval (CI): 0.99, 1.43] at month 24. The numerical difference between EVR+rCNI and MPA+sCNI was mainly caused by an increased proportion of EVR patients with lymphocele and wound dehiscence [7.5% vs. 5.1% (RR: 1.46; 95% CI: 1.04, 2.05) and 3.9% vs. 1.8% (RR: 2.22; 95%CI: 1.28, 3.84), respectively] 20. Conclusion: The immediate introduction of EVR+rCNI after kidney transplantation was associated with an overall comparable incidence of WHAEs versus current standard-of-care over the 24-month study period. There was an increased relative risk of experiencing lymphocele and wound dehiscence but the absolute risks were rather low in both groups 21. Ct.gov identifier: NCT01950819. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Taylor & Francis | - |
dc.relation.isPartOf | EXPERT OPINION ON DRUG SAFETY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Calcineurin Inhibitors / administration & dosage | - |
dc.subject.MESH | Calcineurin Inhibitors / adverse effects* | - |
dc.subject.MESH | Everolimus / administration & dosage | - |
dc.subject.MESH | Everolimus / adverse effects* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents / administration & dosage | - |
dc.subject.MESH | Immunosuppressive Agents / adverse effects* | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Kidney Transplantation | - |
dc.subject.MESH | Lymphocele / epidemiology | - |
dc.subject.MESH | Lymphocele / etiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycophenolic Acid / administration & dosage | - |
dc.subject.MESH | Mycophenolic Acid / adverse effects | - |
dc.subject.MESH | Risk | - |
dc.subject.MESH | Surgical Wound Dehiscence / epidemiology | - |
dc.subject.MESH | Surgical Wound Dehiscence / etiology | - |
dc.subject.MESH | Wound Healing / drug effects* | - |
dc.title | Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Franco Citterio | - |
dc.contributor.googleauthor | Mitchell Henry | - |
dc.contributor.googleauthor | Dean Y Kim | - |
dc.contributor.googleauthor | Myoung Soo Kim | - |
dc.contributor.googleauthor | Duck-Jong Han | - |
dc.contributor.googleauthor | Takashi Kenmochi | - |
dc.contributor.googleauthor | Eytan Mor | - |
dc.contributor.googleauthor | Giuseppe Tisone | - |
dc.contributor.googleauthor | Peter Bernhardt | - |
dc.contributor.googleauthor | Maria Pilar Hernandez Gutierrez | - |
dc.contributor.googleauthor | Yoshihiko Watarai | - |
dc.identifier.doi | 10.1080/14740338.2020.1792441 | - |
dc.contributor.localId | A00424 | - |
dc.relation.journalcode | J03925 | - |
dc.identifier.eissn | 1744-764X | - |
dc.identifier.pmid | 32633157 | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/14740338.2020.1792441 | - |
dc.subject.keyword | Calcineurin inhibitor | - |
dc.subject.keyword | everolimus | - |
dc.subject.keyword | kidney transplantation | - |
dc.subject.keyword | randomized | - |
dc.subject.keyword | safety | - |
dc.subject.keyword | wound healing | - |
dc.contributor.alternativeName | Kim, Myoung Soo | - |
dc.contributor.affiliatedAuthor | 김명수 | - |
dc.citation.volume | 19 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1339 | - |
dc.citation.endPage | 1348 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON DRUG SAFETY, Vol.19(10) : 1339-1348, 2020-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.